吉西他滨调整方案治疗晚期非小细胞肺癌的Ⅱ期临床试验

背景与目的 吉西他滨与铂类的联合化疗是晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）最常用的治疗方案。通常3周方案中的吉西他滨需间隔1周给药。为提高依从性，本研究将吉西他滨第8天给药时间调整为第5天，并评价调整方案一线治疗晚期NSCLC的疗效及安全性。 方法 2007年10月-2009年10月共入组83例晚期NSCLC患者，采用吉西他滨1, 000 mg/m2-1, 250 mg/m2第1天、第5天静脉滴注30 min，联合顺铂75 mg/m2，或联合卡铂（AUC=5）第1天静滴，每21天为1周期，每例至少完成2周期治疗后评价疗效，观察毒性反应及无进展生存期和总生存期。 结果 83例患者的客观有效率为37.3%，中位无进展生存期和中位生存期分别为6.1个月和15.0个月，1年、2年生存率分别为57.8%与16.2%。调整方案的主要不良反应为血液学毒性与胃肠道反应，Ⅲ度-Ⅳ度白细胞、血红蛋白、血小板减少发生率分别为26.5%、10.8%、7.2%，联合顺铂治疗组Ⅲ度-Ⅳ度胃肠道反应发生率为27.5%。无治疗相关死亡。 结论 吉西他滨联合铂类5天调整方案一线治疗晚期NSCLC疗效肯定，毒副反应可耐受，值得进一步开展随机对照研究。

• Publication year

  2012

• Venue

  Zhongguo fei ai za zhi = Chinese journal of lung cancer

• Publication date

  2012-01-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3779/j.issn.1009-3419.2012.01.01PMID 22237116PMCID 5999965
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study.

  2011cited by this paper
• Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer

  2010cited by this paper
• New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine

  2008cited by this paper
• Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.

  2008cited by this paper
• An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH tri

  2008cited by this paper
• Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: Result of a dose-intensity study

  2006cited by this paper
• First line chemotherapy in advanced or metastatic NSCLC.

  2006cited by this paper
• Biweekly Administration of Cisplatin/Gemcitabine in Advanced Nonsmall Cell Lung Cancer

  2005cited by this paper
• Gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: National Cancer Institute Cairo experience.

  2004cited by this paper
• Clinical benefit of gemcitabine plus cisplatin 3-week regimen for patients with advanced non-small cell lung cancer: a prospective observational study.

  2004cited by this paper
• Clinical benefit of gemcitabine plus cisplatin 3-week regimen for patients with advanced non-small-cell lung cancer (NSCLC): a prospective observational study

  2004cited by this paper
• A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life.

  2002cited by this paper
• Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

  2002cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.

  2000cited by this paper
• Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

  2000cited by this paper
• Synergistic interaction between cisplatin and gemcitabine in vitro.

  1996cited by this paper
• Interaction between cisplatin and gemcitabine in vitro and in vivo.

  1995cited by this paper
• Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.

  1994cited by this paper
• A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

  1991cited by this paper

• Integrated pharmacokinetic properties, tissue distribution and metabolism of multiple active constituents in DBD for the treatment of GEM-induced myelosuppression.

  2025cites this paper
• Plasma miR-1273g-3p acts as a potential biomarker for early Breast Ductal Cancer diagnosis.

  2020cites this paper
• Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations

  2014cites this paper